New anticancer agents: in vitro and in vivo evaluation

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• The rapid development of novel anticancer agents necessitates efficient evaluation methods.
• Integrating new anticancer drugs into clinical practice requires rigorous pre-clinical and clinical research.
• Standardized in vitro and in vivo assays are crucial for assessing anticancer agent efficacy.

Purpose of the Study:

• To outline a systematic procedure for evaluating new anticancer agents.
• To propose a method for reducing the number of agents undergoing extensive clinical trials.
• To enhance the efficiency of anticancer drug development pipelines.

Main Methods:

• Utilizing a step-wise experimental approach, starting with in vitro assays.
• Incorporating functional non-clonogenic and clonogenic assays.
• Transitioning from in vitro to in vivo studies for promising candidates.

Main Results:

• A structured methodology enables the reduction of potential anticancer agents.
• The proposed step-wise evaluation minimizes the need for extensive testing of less promising compounds.
• This approach facilitates the selection of highly promising agents for clinical investigation.

Conclusions:

• A sequential in vitro to in vivo assay strategy is effective for evaluating new anticancer agents.
• This systematic approach streamlines the drug development process.
• The proposed method aids in identifying and advancing the most viable anticancer therapies for clinical use.